Menu
Kathy Yi, MBA, is the Chief Operating Officer of Affini-T Therapeutics. She has served as a member of Theseus Pharmaceuticals board of directors since June 2021. She served as Chief Financial Officer of Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) from June 2019 to September 2021. Previously, she served as Executive Vice President, Chief Financial Officer and Secretary of Sangamo Therapeutics, Inc. Prior to Sangamo Therapeutics, Kathy was Head of Finance at Novartis Pharmaceutical Corporation. She held various financial management positions of increasing seniority at Life Technologies Corp., which was acquired by Thermo Fisher Scientific in 2014, including Finance Leader, Corporate FP&A, Director of Finance, M&A/Corporate Development and Director of Finance and Global Manufacturing Operations. Kathy also held increasing roles of responsibilities in corporate finance at Intel Corporation.
Kathy holds a Bachelor of Science in Chemical Engineering from the University of California at Berkeley and a Master of Business Administration from Columbia Business School.
Kathy Yi, MBA, is the Chief Operating Officer of Affini-T Therapeutics. She has served as a member of Theseus Pharmaceuticals board of directors since June 2021. She served as Chief Financial Officer of Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) from June 2019 to September 2021. Previously, she served as Executive Vice President, Chief Financial Officer and Secretary of Sangamo Therapeutics, Inc. Prior to Sangamo Therapeutics, Kathy was Head of Finance at Novartis Pharmaceutical Corporation. She held various financial management positions of increasing seniority at Life Technologies Corp., which was acquired by Thermo Fisher Scientific in 2014, including Finance Leader, Corporate FP&A, Director of Finance, M&A/Corporate Development and Director of Finance and Global Manufacturing Operations. Kathy also held increasing roles of responsibilities in corporate finance at Intel Corporation.
Kathy holds a Bachelor of Science in Chemical Engineering from the University of California at Berkeley and a Master of Business Administration from Columbia Business School.
Lorem ipsum dolor sit amet, consetetur sadi atpscing elitr, sed diam nonumy eirmod tempor eos invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eta loeos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor si amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo ea rebum. Lorem ipsum dolor sit amet, consetetur sadi atpscing elitr, sed diam nonumy eirmod tempor eos invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eta loeos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor si amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo ea rebum. Lorem ipsum dolor si amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo ea rebum. Lorem ipsum dolor sit amet, consetetur sadi atpscing elitr, sed diam nonumy eirmod tempor eos invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eta loeos et
